Legend Biotech (LEGN) Competitors

Legend Biotech logo
$15.99 -1.51 (-8.63%)
Closing price 04:00 PM Eastern
Extended Trading
$16.20 +0.21 (+1.29%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LEGN vs. ASND, BBIO, HALO, SMMT, and KYMR

Should you buy Legend Biotech stock or one of its competitors? Legend Biotech's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), Summit Therapeutics (SMMT), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Legend Biotech compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Ascendis Pharma A/S has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Ascendis Pharma A/S has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$814.57M21.09-$258M$15.3018.00
Legend Biotech$1.36B2.50-$296.80M-$0.01N/A

70.9% of Legend Biotech shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Legend Biotech had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 37 mentions for Legend Biotech and 29 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Legend Biotech's score of -0.14 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
7 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral

Ascendis Pharma A/S has a net margin of 73.26% compared to Legend Biotech's net margin of -0.02%. Ascendis Pharma A/S's return on equity of 32.47% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S73.26% 32.47% 13.26%
Legend Biotech -0.02%-0.03%-0.02%

Ascendis Pharma A/S presently has a consensus price target of $313.52, suggesting a potential upside of 13.85%. Legend Biotech has a consensus price target of $50.85, suggesting a potential upside of 190.55%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.90
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Ascendis Pharma A/S beats Legend Biotech on 11 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

BridgeBio Pharma currently has a consensus target price of $104.42, suggesting a potential upside of 33.36%. Legend Biotech has a consensus target price of $50.85, suggesting a potential upside of 190.55%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Legend Biotech had 25 more articles in the media than BridgeBio Pharma. MarketBeat recorded 37 mentions for Legend Biotech and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Legend Biotech's score of -0.14 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral

Legend Biotech has a net margin of -0.02% compared to BridgeBio Pharma's net margin of -59.84%. BridgeBio Pharma's return on equity of 0.00% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-59.84% N/A -39.81%
Legend Biotech -0.02%-0.03%-0.02%

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Legend Biotech has higher revenue and earnings than BridgeBio Pharma. Legend Biotech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A
Legend Biotech$1.36B2.50-$296.80M-$0.01N/A

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

BridgeBio Pharma beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Halozyme Therapeutics?

Legend Biotech (NASDAQ:LEGN) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Halozyme Therapeutics has a net margin of 26.93% compared to Legend Biotech's net margin of -0.02%. Halozyme Therapeutics' return on equity of 751.81% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-0.02% -0.03% -0.02%
Halozyme Therapeutics 26.93%751.81%23.84%

Legend Biotech presently has a consensus target price of $50.85, indicating a potential upside of 190.55%. Halozyme Therapeutics has a consensus target price of $108.18, indicating a potential upside of 7.89%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Legend Biotech is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

Halozyme Therapeutics has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$1.36B2.50-$296.80M-$0.01N/A
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Legend Biotech has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

In the previous week, Legend Biotech had 25 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 37 mentions for Legend Biotech and 12 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.13 beat Legend Biotech's score of -0.14 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Halozyme Therapeutics beats Legend Biotech on 12 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Summit Therapeutics has a beta of -1.49, meaning that its stock price is 249% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

In the previous week, Legend Biotech had 30 more articles in the media than Summit Therapeutics. MarketBeat recorded 37 mentions for Legend Biotech and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Legend Biotech's score of -0.14 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summit Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -0.02%. Legend Biotech's return on equity of -0.03% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -138.82% -117.11%
Legend Biotech -0.02%-0.03%-0.02%

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 81.8% of Summit Therapeutics shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech has higher revenue and earnings than Summit Therapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A
Legend Biotech$1.36B2.50-$296.80M-$0.01N/A

Summit Therapeutics currently has a consensus price target of $28.61, indicating a potential upside of 102.17%. Legend Biotech has a consensus price target of $50.85, indicating a potential upside of 190.55%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Summit Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Legend Biotech beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Kymera Therapeutics has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

In the previous week, Legend Biotech had 33 more articles in the media than Kymera Therapeutics. MarketBeat recorded 37 mentions for Legend Biotech and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Legend Biotech's score of -0.14 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral

Legend Biotech has a net margin of -0.02% compared to Kymera Therapeutics' net margin of -285.33%. Legend Biotech's return on equity of -0.03% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -22.39% -20.48%
Legend Biotech -0.02%-0.03%-0.02%

70.9% of Legend Biotech shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech has higher revenue and earnings than Kymera Therapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A
Legend Biotech$1.36B2.50-$296.80M-$0.01N/A

Kymera Therapeutics presently has a consensus target price of $139.16, suggesting a potential upside of 9.09%. Legend Biotech has a consensus target price of $50.85, suggesting a potential upside of 190.55%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Legend Biotech beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LEGN vs. The Competition

MetricLegend BiotechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.59B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E RatioN/A24.2434.3430.11
Price / Sales3.0114.858.005.34
Price / CashN/A21.8921.0222.34
Price / Book2.434.354.763.85
Net Income-$296.80M-$24.19M$3.52B$393.14M
7 Day Performance-34.17%-7.26%-5.34%-4.53%
1 Month Performance-13.47%-4.96%-3.61%-5.86%
1 Year Performance-47.21%-2.87%0.01%-7.78%

Legend Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LEGN
Legend Biotech
3.2132 of 5 stars
$15.99
-8.6%
$50.85
+218.0%
-42.2%$3.59B$1.03BN/A2,965
ASND
Ascendis Pharma A/S
4.252 of 5 stars
$259.85
+1.2%
$305.95
+17.7%
+34.7%$16.09B$814.57M20.161,189
BBIO
BridgeBio Pharma
3.622 of 5 stars
$77.93
+4.9%
$104.26
+33.8%
+17.9%$15.17B$502.08MN/A839
HALO
Halozyme Therapeutics
4.2791 of 5 stars
$102.92
-0.7%
$106.73
+3.7%
+43.2%$14.79B$1.40B26.44423
SMMT
Summit Therapeutics
2.6441 of 5 stars
$17.84
+9.2%
$28.61
+60.4%
-21.5%$12.93BN/AN/A265

Related Companies and Tools


This page (NASDAQ:LEGN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners